|
Reference
Year | N | Stage | Chemotherapy regime | Radiotherapy
Dose (Gray) | Surgery | Outcome |
|
[10]
1985 | 1 | Locally advanced
Female | Mitomycin C and
5-fluorouracil | | | Disease-free at 30 months |
|
[11]
1989 | 1 | Locally advanced
SCC | Mitomycin C 15 mg/m2 and
5-fluorouracil 1250 mg/m2 | 40 Gy in 20 fractions | | Disease-free at 28 months |
|
[12]
1992 | 1 | Locally advanced
SCC
Male | 5-Fluorouracil
1 mg/m2 and
mitomycin C 5 mg/m2 | 40 Gy in 20 fractions | Distal urethrectomy with en bloc resection of the adjacent corpora cavernosa | Cure |
|
[13]
1995 | 4 | Locally advanced
SCC
Male and female | 5-Fluorouracil (100 mg/m2) and mitomycin C (15 mg/m2) | 30–50 Gy | | 43–98 months median survival |
|
[14]
1995 | 1 | Locally advanced
SCC
Male | 5-Fluorouracil
mitomycin C | | | |
|
[15]
1995 | 1 | Stage IVB
SCC | 5-Fluorouracil 1400 mg and mitomycin C 18 mg | 55.80 Gy in 31 fractions | | Disease free at 5.5 yrs |
|
[16]
1998 | 3 | Locally advanced
SCC | 5-Fluorouracil and cisplatin | 45 Gy | Distal urethrectomy | 50% DFS |
|
[17]
2004 | 2 | Locally advanced
SCC | 5-Fluorouracil 750 mg/m2 and cisplatin 60 mg/m2 | 60 Gy in 30 fractions | | One LR at 42 months
The other is disease-free at 27 months |
|
[18]
2008 | 18 | T2N0 (11%)
T3N0 (44%)
T4N0 (11%)
TXN1 (6%)
TXN2 (28%) | 5-Fluorouracil (1000 mg/m2) and mitomycin C (10 mg/m2) | 45–55 Gy 25 fractions | Salvage surgery in selected cases | 54% 5 year DFS chemoradiation
72% 5 year DFS chemoradiation and salvage surgery |
|
[19]
2011 | 1 | Locally advanced | Cisplatin weekly
Following surgery: Adjuvant cisplatin and 5-fluorouracil
Doses not available | 60 Gy in 30 fractions | Salvage surgery 12 weeks after chemoradiotherapy due to local progressive disease: radical en bloc resection, abdominoperineal resection, right inguinal superficial lymphadenectomy, cystoprostatectomy with ileal conduit, penectomy, scrotal incision, and bilateral orchiectomy. | Symptom control for 5 months |
|
